Additionally, the EMERGE trial (NCT03812796) [96], conducted by the Royal Marsden NHS Foundation Trust, evaluated the efficacy of domatinostat, a selective HDAC1 inhibitor, in combination with avelumab, a PD-L1 antibody, in patients with microsatellite stable CRC or esophagogastric adenocarcinoma (OGA) previously treated with chemotherapy. This evidence concerns the gene CD274 and colorectal carcinoma.